Theolytics has initiated a Phase I/IIa trial (OCTOPOD) of THEO-260, an oncolytic immunotherapy, in patients with advanced platinum-resistant ovarian cancer (PROC).
Theolytics has initiated a Phase I/IIa trial of THEO-260, an oncolytic immunotherapy, in patients with advanced-stage platinum-resistant ovarian cancer (PROC).
Theolytics has been awarded a £2m grant from Innovate UK to support a Phase I clinical trial of THEO-260 for advanced-stage platinum-resistant ovarian cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.